Decreased Expression of SOX7 is Correlated with Poor Prognosis in Lung Adenocarcinoma Patients

Li, Bing; Ge, Zhiping; Song, Shipeng; Zhang, Shengbin; Hong, Yan; Huang, Boyun; Yang-de, Zhang

doi:10.1007/s12253-012-9542-8

Cited by 38 publications

(46 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hayano T et al found SOX7 was a novel tumor suppressor gene which was silenced in lung cancer [21]. Li B et al also reported that decreased SOX7 level was correlated with poor prognosis of lung adenocarcinoma [22]. Zhou X et al found that SOX7 was involved in aspirin-mediated growth inhibition of colorectal cancer cells [23].…”

Section: Discussionmentioning

confidence: 99%

miR-24 promotes the proliferation and invasion of HCC cells by targeting SOX7

She

Ming

et al. 2014

Tumor Biol.

View full text Add to dashboard Cite

Accumulating evidence shows that microRNAs (miRNAs) are involved in the development and progression of multiple tumors, including hepatocellular carcinoma (HCC). Recent studies have found that miR-24 acts as an oncogene in several tumors; however, the function of miR-24 in HCC remains unclear. In this study, we found that miR-24 was increased in HCC tissues and cell lines. Inhibition of miR-24 by inhibitor significantly suppressed HCC cells proliferation, migration, and invasion. Furthermore, the sex-determining region Y (SRY)-box 7 (SOX7), a putative tumor suppressor, was found to be a target of miR-24 in HCC cells. Forced expression of SOX7 substantially attenuated the oncogenic effects of miR-24. Those results strongly suggest that miR-24 plays important role in HCC development partially by targeting SOX7.

show abstract

Section: Discussionmentioning

confidence: 99%

miR-24 promotes the proliferation and invasion of HCC cells by targeting SOX7

She

Ming

et al. 2014

Tumor Biol.

View full text Add to dashboard Cite

show abstract

“…PITX2 is a downstream effector of Wnt/β-catenin signaling. Deregulation of Wnt signaling is strongly associated with LAC progression [18,19]. More recently, PITX2 can activate the proliferation of cancer cells by inducing the expression of canonical Wnt ligand genes, and in turn activates the signaling pathway [20].…”

Section: Discussionmentioning

confidence: 99%

Identification of stage-specific biomarkers in lung adenocarcinoma based on RNA-seq data

Liang

Liu

2015

Tumor Biol.

View full text Add to dashboard Cite

Tumorigenesis is a multistep process that attributes to the sequential accumulation of abnormal expression in key oncogenes or tumor suppressors. We aimed to identify stage-specific biomarkers to distinguish lung adenocarcinoma (LAC) stages in cancer progression. RNA-sequencing data of LAC and matched adjacent non-cancer tissues were downloaded from the Cancer Genome Atlas, including 29 pairs of samples from LAC at stage I, 14 from LAC at stage II, 13 from LAC at stage III, and 1 from LAC at stage IV. Differentially expressed genes (DEGs) were analyzed for each case at different stages of LAC. DEGs were further annotated based on transcription factor data information, tumor-associated gene database, and protein-protein interaction database. Functional annotation was performed for genes in PPI network by DAVID online tool. Our analysis identified 11 high-frequency DEGs in the stage I, 29 in the stage II, and 90 in the stage III of LAC. Among them, eight genes were significantly correlated with LAC stages and identified as biomarkers in LAC progression. ANGPTL5, C7orf16, EDN3, LOC150622, HOXA11AS, IL1F5, and USH1G significantly distinguished stage III from stages I and II. GJB6 was significantly enriched in the gap junction trafficking pathway, while C7orf16 and EDN3 were enriched in Wnt signaling pathway, cell cycle, and G protein-coupled receptor (GPCR) signaling. Up-regulated GJB6 especially in LAC stage II and down-regulated C7orf16 and EDN3 specifically in stage III were identified as biomarkers for distinguishing cancer stage in tumor progression through dysregulating gap junction, Wnt signaling, and GPCR signaling pathways.

show abstract

“…Additionally, SOX7 may have potential usage as an independent prognostic marker in prostate and lung cancers as well as MDS patients [11,12,29]. Several lines of evidence indicate SOX7 as a negative regulator of the Wnt/β-catenin signaling pathway [14,15].…”

Section: Discussionmentioning

confidence: 99%

“…Additionally, SOX7 may be involved in aspirin-mediated growth inhibition of COX2 colorectal cancer cells, in which aspirin may up-regulate the expression of SOX7 by activating the MAPK [17]. There are also reports indicating that the decreased expression of SOX7 is an important feature of lung adenocarcinoma [12]. Based on whole genome analysis to measure the expression of SOX7 on a series of non-small cell lung cancers (NSCLC), investigators have shown that SOX7 is a novel tumor suppressor gene silenced in the majority of NSCLC [19].…”

Section: Introductionmentioning

confidence: 99%

Reduced expression of SOX7 in ovarian cancer: a novel tumor suppressor through the Wnt/β-catenin signaling pathway

Liu

Yan

et al. 2014

J Ovarian Res

View full text Add to dashboard Cite

BackgroundProducts of the SOX gene family play important roles in the life process. One of the members, SOX7, is associated with the development of a variety of cancers as a tumor suppression factor, but its relevance with ovarian cancer was unclear. In this study, we investigated the involvement of SOX7 in the progression and prognosis of epithelial ovarian cancer (EOC) and the involved mechanisms.MethodsExpression profiles in two independent microarray data sets were analyzed for SOX7 between malignant and normal tissues. The expression levels of SOX7 in EOC, borderline ovarian tumors and normal ovarian tissues were measured by immunohistochemistry. We also measured levels of COX2 and cyclin-D1 to examine their possible involvement in the same signal transduction pathway as SOX7.ResultsThe expression of SOX7 was significantly reduced in ovarian cancer tissues compared with normal controls, strongly indicating that SOX7 might be a negative regulator in the Wnt/β-catenin pathway in ovarian cancer. By immunohistochemistry staining, the protein expression of SOX7 showed a consistent trend with that of the gene expression microarray analysis. By contrast, the protein expression level of COX2 and cyclin-D1 increased as the tumor malignancy progressed, suggesting that SOX7 may function through the Wnt/β-catenin signaling pathway as a tumor suppressor. In comparison between the protein expression levels of SOX7 with pathological features of the cancer, we found that SOX7 was down-regulated mainly in serous cystadenocarcinoma and advanced stages of the cancers.ConclusionsThe expression of SOX7 correlates with tumor progression as a tumor suppressor, possibly through the Wnt/β-catenin signaling pathway in ovarian cancers, suggesting that SOX7 may be a promising prognostic marker.Electronic supplementary materialThe online version of this article (doi:10.1186/s13048-014-0087-1) contains supplementary material, which is available to authorized users.

show abstract

Decreased Expression of SOX7 is Correlated with Poor Prognosis in Lung Adenocarcinoma Patients

Cited by 38 publications

References 20 publications

miR-24 promotes the proliferation and invasion of HCC cells by targeting SOX7

miR-24 promotes the proliferation and invasion of HCC cells by targeting SOX7

Identification of stage-specific biomarkers in lung adenocarcinoma based on RNA-seq data

Reduced expression of SOX7 in ovarian cancer: a novel tumor suppressor through the Wnt/β-catenin signaling pathway

Contact Info

Product

Resources

About